1. Home
  2. AKBA vs FF Comparison

AKBA vs FF Comparison

Compare AKBA & FF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • FF
  • Stock Information
  • Founded
  • AKBA 2007
  • FF N/A
  • Country
  • AKBA United States
  • FF United States
  • Employees
  • AKBA N/A
  • FF N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • FF Major Chemicals
  • Sector
  • AKBA Health Care
  • FF Industrials
  • Exchange
  • AKBA Nasdaq
  • FF Nasdaq
  • Market Cap
  • AKBA 336.2M
  • FF 270.9M
  • IPO Year
  • AKBA 2014
  • FF N/A
  • Fundamental
  • Price
  • AKBA $1.91
  • FF $6.13
  • Analyst Decision
  • AKBA Strong Buy
  • FF Strong Buy
  • Analyst Count
  • AKBA 2
  • FF 1
  • Target Price
  • AKBA $5.75
  • FF $0.80
  • AVG Volume (30 Days)
  • AKBA 2.3M
  • FF 255.4K
  • Earning Date
  • AKBA 11-07-2024
  • FF 11-08-2024
  • Dividend Yield
  • AKBA N/A
  • FF 3.87%
  • EPS Growth
  • AKBA N/A
  • FF N/A
  • EPS
  • AKBA N/A
  • FF 0.91
  • Revenue
  • AKBA $169,879,000.00
  • FF $339,451,000.00
  • Revenue This Year
  • AKBA N/A
  • FF N/A
  • Revenue Next Year
  • AKBA $3.23
  • FF N/A
  • P/E Ratio
  • AKBA N/A
  • FF $6.85
  • Revenue Growth
  • AKBA N/A
  • FF N/A
  • 52 Week Low
  • AKBA $0.80
  • FF $4.15
  • 52 Week High
  • AKBA $2.48
  • FF $8.36
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 68.47
  • FF 58.20
  • Support Level
  • AKBA $1.30
  • FF $5.96
  • Resistance Level
  • AKBA $2.01
  • FF $6.30
  • Average True Range (ATR)
  • AKBA 0.12
  • FF 0.14
  • MACD
  • AKBA 0.04
  • FF 0.00
  • Stochastic Oscillator
  • AKBA 78.52
  • FF 63.27

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About FF FutureFuel Corp. Common shares

FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuel segment sells biodiesel and other petroleum products. Its fuels are made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment sells products that are used in the production of agricultural chemicals, which include herbicides, coatings, and cleaning products, such as detergents.

Share on Social Networks: